ethyl lonidamine | 50264-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: ethyl lonidamine
• 英文别名: 1-(2,4-dichloro-benzyl)-1H-indazole-3-carboxylic acid ethyl ester；1-[(2,4-dichlorobenzyl)-1H-indazole]-3-carboxylic acid ethyl ester；1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid ethyl ester；ethyl 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylate；ethyl 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylate
• CAS: 50264-84-1
• 化学式: C₁₇H₁₄Cl₂N₂O₂
• 分子量: 349.216
• InChiKey: POLYCXULTAVWNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  493.2±40.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[1-(4-chloro-2-methylbenzyl)-1H-indazol-3-yl]propan-2-ol 、 ethyl lonidamine 生成 2-[1-(2,4-dichlorobenzyl)-1H-indazol-3-yl]propan-2-ol
  参考文献：
  名称：

  1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40

  摘要：

  本发明涉及根据权利要求中所述的式(I)所描述的新型1-苄基-3-羟甲基吲唑衍生物，以及包含它们的制药组合物和与药学上可接受的载体一起使用。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备活性用于治疗基于MCP-1、CX3CR1和p40表达的疾病的制药组合物，并将其用于治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法。

  公开号：

  US20110082141A1
• 作为产物：
  描述：

  乙醇 、 氯尼达明 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以84%的产率得到ethyl lonidamine
  参考文献：
  名称：

  MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES

  摘要：

  提供了细胞代谢调节剂的组成，通常以靶向细胞糖酵解为目标，最好带有一个靶向基团，直接或间接连接到抑制剂，或连接到纳米颗粒或其他递送载体上，并提供了用于治疗癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的方法。还提供了包括靶向调节剂和药学上可接受的载体的药物组合物。这些药物组合物可以以有效剂量给需要的受试者使用，以减少癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的症状之一或多个，独立使用或在放疗等进一步治疗之前或同时使用。

  公开号：

  US20180028647A1

文献信息

• LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT
  申请人：Georg Ingrid Gunda

  公开号：US20110060003A1

  公开（公告）日：2011-03-10

  Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

  生育管理可以包括：根据公式I的一个或多个剂量给予受试者一种化合物，以降低受试者的生育能力。生育管理还可以包括给予化合物的有效量：破坏雄性受试者的精原细胞功能；抑制受试者的精子生成；减少受试者的睾丸重量；减少雌性受试者的卵巢重量；减少雌性受试者的血清孕酮；破坏雌性受试者的卵巢滤泡功能；导致受试者可逆的生育能力。为了恢复生育能力，该方法可以包括停止给予化合物以使受试者恢复生育能力。该化合物可以用于对受试者进行不可逆的绝育。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
  申请人：Guglielmotti Angelo

  公开号：US08461194B2

  公开（公告）日：2013-06-11

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型1-苄基-3-羟甲基吲唑衍生物，其化学式（I）如权利要求中所述，以及包含它们的制药组合物和药用载体。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于MCP-1、CX3CR1和p40表达的疾病具有活性的制药组合物，以及它们在治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法中的使用。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
  申请人：AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A.

  公开号：US09255073B2

  公开（公告）日：2016-02-09

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型的1-苄基-3-羟甲基吲唑衍生物，其化学式（I）如权利要求书所述，并且涉及包含它们的制药组合物，以及与药学上可接受的载体一起使用的制药组合物。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于 MCP-1、CX3CR1 和 p40 表达的疾病具有活性的制药组合物，并将它们用于治疗或预防基于 MCP-1、CX3CR1 和 p40 表达的疾病的方法。
• LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
  申请人：Georg Ingrid Gunda

  公开号：US20090197911A1

  公开（公告）日：2009-08-06

  Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and/or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.

  Lonidamine衍生物可用于治疗、抑制和/或预防多囊肾病（PKD）的方法中。因此，可以在治疗上有效的剂量下向受体内投入Lonidamine衍生物以抑制和/或预防多囊肾病（PKD）。这可以包括向受体注射治疗上有效的Lonidamine衍生物剂量以抑制CFTR和/或Hsp90或其生物途径。此外，该方法可以包括向受体注射治疗上有效的Lonidamine衍生物剂量以抑制ErbB2、Src、Raf-1、B-Raf、MEK、Cdk4、NKCC1或其组合。例如，Lonidamine衍生物的治疗上有效的剂量可以配置为在或邻近肾细胞中提供约0.25 uM或更高或更低的浓度。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP2262778A2

  公开（公告）日：2010-12-22